Fast and robust quantitative MRI with tissue-susceptibility mapping of the human brain
Project Number1K99EB035178-01A1
Former Number1K99EB035178-01
Contact PI/Project LeaderWANG, NAN
Awardee OrganizationSTANFORD UNIVERSITY
Description
Abstract Text
Project Summary/Abstract:
T2* mapping and quantitative susceptibility mapping (QSM) are vital for in vivo iron quantification. They can
track the subtle changes in tissue compositions during early brain development; they can provide valuable
characteristics of lesions in Multiple Sclerosis (MS) for structural, pathological, and dynamic information. T2* and
QSM are commonly estimated using multi-echo gradient echo (GRE), which suffers from long scan time (5-10
minutes) and sensitivity to motion and B0 perturbations, significantly limiting its clinical accessibility and impeding
its potential for fine tissue characterization towards submillimeter resolution.
This project aims to develop and validate a rapid, distortion- and blurring-free, and motion- and B0-robust
technique for submillimeter-resolution T2* and QSM quantification, and translate it to applications on challenging
populations, including infants and MS patients, demonstrating its potential for wide neuroscientific and clinical
applications. The goal is fulfilled through three Specific Aims:
In Aim 1, we will develop and optimize a highly efficient spherical-coverage echo-planar time-resolved
imaging (sEPTI) framework for whole-brain distortion- and blurring-free T2* and QSM quantification. We will
leverage a subspace-based unrolled deep-learning network for SNR-boosting reconstruction to achieve a 4x
reduction in scan time on top of the already-fast state-of-the-art EPTI techniques.
In Aim 2, we will develop a 3.5-ms multi-channel SPINS-trajectory navigator and combine it with the sEPTI
technique as nasEPTI to achieve accurate motion and δB! estimation per TR with 70 ms latency. A supervised
deep learning network will be developed to achieve fast and accurate estimation of motion and δB! in <5ms.
Taken together, we will develop a synergistic per-TR prospective motion correction and retrospective B0
correction pipeline based on the rapid deep learning inference to accomplish a robust nasEPTI technique for
artifact-minimized T2* weighted images, and T2* and QSM quantification.
In Aim 3, nasEPTI will first be validated on 20 motion-prone infant subjects on 3-Tesla scanners with 0.7mm3
isotropic resolution and 1-minute scan time to demonstrate its robustness to motion and B0 perturbations. In
parallel, this technique will be translated to 7-Tesla systems for a protocol of 0.35 mm isotropic resolution and 6-
minute scan time. Finally, we will validate the 7T nasEPTI protocol on clinically suspected MS patients with
cortical lesions, where T2* and QSM provide critical pathological information about the lesions.
The expected outcome is that the proposed techniques achieve distortion- and blurring-free, motion- and
B0-robust high-resolution T2* and QSM quantification. They are consistent with conventional multi-echo GRE in
terms of T2* and QSM values, but provide enhanced image quality with significantly reduced artifacts. This will
enable mesoscale iron characterization within a scientifically and clinically feasible time, facilitating its access to
general populations, including motion-prone pediatric and geriatric groups.
Public Health Relevance Statement
Project Narrative
T2* mapping and quantitative susceptibility mapping (QSM) are critical MRI techniques for in vivo iron
quantification, providing crucial information about brain development and neurodegenerative diseases, including
Multiple Sclerosis (MS). However, T2* and QSM have yet to be widely adopted in clinical practices due to long
scan time and sensitivity to motion and B0 fluctuations. This work aims to develop and validate a motion- and B0-
robust technique for T2* and QSM quantification using the spherical echo planar time-resolved imaging (sEPTI),
deep learning-based image reconstruction, prospective motion correction, and retrospective B0 correction, which
will significantly improve the image quality and accessibility of T2* and QSM and widen their clinical and scientific
applicability in general populations.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
009214214
UEI
HJD6G4D6TJY5
Project Start Date
01-August-2024
Project End Date
31-July-2026
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$103,441
Direct Costs
$95,779
Indirect Costs
$7,662
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$103,441
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1K99EB035178-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1K99EB035178-01A1
Patents
No Patents information available for 1K99EB035178-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1K99EB035178-01A1
Clinical Studies
No Clinical Studies information available for 1K99EB035178-01A1
News and More
Related News Releases
No news release information available for 1K99EB035178-01A1
History
No Historical information available for 1K99EB035178-01A1
Similar Projects
No Similar Projects information available for 1K99EB035178-01A1